P852 A multicentre, double-blind, randomised clinical trial of par-enteral cefepime in the treatment of acute bacterial infections

In vitro Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China

“…The relatively high activities of fourth-generation cephalosporins against Enterobacteriaceae may be attributed to the low affinity for chromosome-mediated AmpC β-lactamases (D'Angelo et al, 2016), which are the common β-lactamases in Enterobacteriaceae isolates from China. A multicenter, double-blind, randomized clinical trial in China revealed equal clinical efficacy and safety of intravenous cefoselis and cefepime injection for the treatment of acute, moderate, and severe bacterial infections (Liu et al, 2014).…”

Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells

“…Cefoselis is a widely used β‐lactam antibiotic with high efficacy and safety. 5 Here, we identified cefoselis as a GRP78‐targeting agent for eliminating breast CSCs.…”

“…Cefoselis brought little hepatotoxicity, nephrotoxicity, and no aggravation of leukopenia when coadministrated with paclitaxel (Table S3). 5 The pharmacokinetic study demonstrated that the Cmax and AUC 0 -t values of cefoselis were 27.367 mg/L and 38.337 mg/L⋅h, and the t 1/2 was determined as 2.346 h (Figure 3I). Moreover, cefoselis had a relatively high concentration in breast tumours, just behind the kidney (Figure 3J).…”

“…Cefoselis is a widely used β-lactam antibiotic with high efficacy and safety. 5 Here, we identified cefoselis as a GRP78-targeting agent for eliminating breast CSCs.We first evaluate the clinical implications of GRP78 expression in breast cancer and its potential as a druggable target. Bioinformatics analysis indicated that GRP78 levels were higher in tumours than in para-tumour tissues.…”